Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Thermo Fisher Scientific    TMO

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : Launches New MAS Omni Infectious Disease Quality Controls

share with twitter share with LinkedIn share with facebook
07/02/2020 | 09:36am EDT

Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific MAS Omni Infectious Disease quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B & C virus, Syphilis and HTLV I/II.

Serology testing for infectious diseases continues to be on the rise and newer instrument platforms are offering serology markers with improved sensitivity than previously available. In addition, there is continued progression with infectious disease screening protocols requiring serology testing for diagnosis, monitoring and treatment of infectious agents.

The Thermo Scientific MAS Omni Infectious positive and negative quality controls are third-party, independent external controls used to assess the performance of serological assays for infectious diseases. Our new control set supports assays for HIV, Hepatitis C, Hepatitis B, HTLV and Syphilis. As with all Thermo Scientific MAS Quality Controls users can efficiently monitor assay performance, streamline operations and potentially reduce your spending without sacrificing quality or throughput.

'We are expanding our quality control offering into a space which continues to increase each year as new pharma drugs are developed and enabling better identification and treatment for infectious diseases. Our team is committed to providing innovative solutions to support our customers productivity,' said Fernando Beils, vice president and general manager, Thermo Fisher's niche diagnostics business. 'The Thermo Scientific MAS Omni Infectious Controls are the first in a line of products we are continuing to develop to support the monitoring of in vitro diagnostic tests.'

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Contact:

Chris Rapcan

Tel: 1 (815) 572-1198

Email: chris.rapcan@thermofisher.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
Latest news on THERMO FISHER SCIENTIFIC
10:07aTHERMO FISHER SCIENTIFIC : China Approves Thermo Fisher Scientific's African Swi..
PU
07/31THERMO FISHER SCIENTIFIC : Management's Discussion and Analysis of Financial Con..
AQ
07/31THERMO FISHER SCIENTIFIC : Scientific nProber IV Delivers Faster Easier Failure ..
AQ
07/29THERMO FISHER SCIENTIFIC : and Lyell Immunopharma Form Cell Therapy Manufacturin..
AQ
07/29THERMO FISHER SCIENTIFIC : - Chemical Analyzer Now Enhances Identification of Lo..
AQ
07/28THERMO FISHER SCIENTIFIC : Expands GlobalAccess Sequencing Program
AQ
07/24THERMO FISHER SCIENTIFIC : - FDA Clears First Blood Test for Identifying a Novel..
AQ
07/22GLOBAL MARKETS LIVE: Snap, Microsoft, Tesla…
07/22THERMO FISHER SCIENTIFIC : 2Q Profit, Sales Rise on Covid-Related Products
DJ
07/22THERMO FISHER SCIENTIFIC INC. : Results of Operations and Financial Condition, F..
AQ
More news
Financials (USD)
Sales 2020 28 041 M - -
Net income 2020 4 456 M - -
Net Debt 2020 12 658 M - -
P/E ratio 2020 37,4x
Yield 2020 0,21%
Capitalization 166 B 166 B -
EV / Sales 2020 6,36x
EV / Sales 2021 5,98x
Nbr of Employees 75 000
Free-Float 90,4%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 442,72 $
Last Close Price 419,09 $
Spread / Highest target 19,3%
Spread / Average Target 5,64%
Spread / Lowest Target -35,3%
EPS Revisions
Managers
NameTitle
Marc N. Casper Chairman, President & Chief Executive Officer
Mark P. Stevenson Chief Operating Officer & Executive Vice President
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Scott M. Sperling Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERMO FISHER SCIENTIFIC29.00%163 754
DANAHER CORPORATION32.79%144 578
INTUITIVE SURGICAL, INC.15.95%80 214
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.89.64%60 477
ILLUMINA, INC.15.20%56 178
BOSTON SCIENTIFIC CORPORATION-14.71%54 958